Cytosorbents Corp (NASDAQ: CTSO) closed the day trading at $0.88 down -9.27% from the previous closing price of $0.97. In other words, the price has decreased by -$0.0899 from its previous closing price. On the day, 522785 shares were traded.
Ratios:
For a better understanding of CTSO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.51 and its Current Ratio is at 1.77. In the meantime, Its Debt-to-Equity ratio is 0.79 whereas as Long-Term Debt/Eq ratio is at 0.66.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on September 07, 2023, initiated with a Buy rating and assigned the stock a target price of $4.
On September 17, 2020, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on September 17, 2020, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 13 ’23 when Chan Phillip P. bought 75,188 shares for $1.33 per share. The transaction valued at 100,000 led to the insider holds 1,068,704 shares of the business.
BATOR MICHAEL G. bought 37,594 shares of CTSO for $50,000 on Dec 13 ’23. The Director now owns 125,394 shares after completing the transaction at $1.33 per share. On Dec 13 ’23, another insider, BLOCH KATHLEEN P., who serves as the Chief Financial Officer of the company, bought 37,594 shares for $1.33 each. As a result, the insider paid 50,000 and bolstered with 467,941 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTSO now has a Market Capitalization of 48.52M and an Enterprise Value of 52.70M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.26 while its Price-to-Book (P/B) ratio in mrq is 2.05. Its current Enterprise Value per Revenue stands at 1.68 whereas that against EBITDA is -1.97.
Stock Price History:
Over the past 52 weeks, CTSO has reached a high of $4.29, while it has fallen to a 52-week low of $0.84. The 50-Day Moving Average of the stock is 0.9830, while the 200-Day Moving Average is calculated to be 2.0001.
Shares Statistics:
Over the past 3-months, CTSO traded about 316.68K shares per day on average, while over the past 10 days, CTSO traded about 121.32k shares per day. A total of 54.24M shares are outstanding, with a floating share count of 46.04M. Insiders hold about 11.82% of the company’s shares, while institutions hold 35.98% stake in the company. Shares short for CTSO as of Feb 29, 2024 were 1.72M with a Short Ratio of 5.42, compared to 1.8M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.29% and a Short% of Float of 3.37%.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.13, while EPS last year was -$0.17. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.11 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.3 and -$0.78 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.21, with 3 analysts recommending between -$0.14 and -$0.29.
Revenue Estimates
1 analysts predict $9.7M in revenue for the current quarter. It ranges from a high estimate of $9.7M to a low estimate of $9.7M. As of the current estimate, Cytosorbents Corp’s year-ago sales were $9.45M, an estimated increase of 2.70% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $10.6M, an increase of 12.50% over than the figure of $2.70% in the same quarter last year. There is a high estimate of $10.6M for the next quarter, whereas the lowest estimate is $10.6M.
A total of 4 analysts have provided revenue estimates for CTSO’s current fiscal year. The highest revenue estimate was $50.6M, while the lowest revenue estimate was $27.83M, resulting in an average revenue estimate of $41.31M. In the same quarter a year ago, actual revenue was $36.35M, up 13.60% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $55.4M in the next fiscal year. The high estimate is $58.24M and the low estimate is $49.76M. The average revenue growth estimate for next year is up 34.10% from the average revenue estimate for this year.
